Establishment and application of a predictive model for gefitinib-induced severe rash based on pharmacometabolomic profiling and polymorphisms of transporters in non-small cell lung cancer

BACKGROUND: Rash is a well-known predictor of survival for patients with gefitinib therapy with non-small cell lung cancer (NSCLC). However, whether patients with more severe rash obtain the more survival benefits from gefitinib is still unknown, and predicted model for severe rash is needed. METHOD...

Descripción completa

Detalles Bibliográficos
Autores principales: Guan, Shaoxing, Chen, Xi, Xin, Shuang, Liu, Shu, Yang, Yunpeng, Fang, Wenfeng, Huang, Yan, Zhao, Hongyun, Zhu, Xia, Zhuang, Wei, Wang, Fei, Feng, Wei, Zhang, Xiaoxu, Huang, Min, Wang, Xueding, Zhang, Li
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Neoplasia Press 2020
Materias:
Original article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7689337/
https://www.ncbi.nlm.nih.gov/pubmed/33221684
http://dx.doi.org/10.1016/j.tranon.2020.100951

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7689337/
https://www.ncbi.nlm.nih.gov/pubmed/33221684
http://dx.doi.org/10.1016/j.tranon.2020.100951

Ejemplares similares